Anti-Tuberculosis Therapeutics Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

The anti-tuberculosis therapeutics market was valued at USD 1.45 billion in 2025. It is poised to grow at a CAGR of 7.60% during the forecast period of 2026-2035, and reach USD 3.03 billion by 2035. The market growth is driven by the rising global incidence of tuberculosis, increasing investment in pharmaceutical research and development, and the escalating adoption of advanced therapeutic regimens across the 8 major markets.

Key Market Trends and Insights

• Based on disease type, the active TB segment is expected to hold a significant share in the market.
• By therapy type, the first-line therapy segment recorded the highest share of approximately 62% in the historical period.
• Based on the route of administration, the oral segment accounted for nearly 73% in the historical period.

Market Size and Forecast

• Market Size (2025): USD 1.45 billion
• Projected Market Size (2035): USD 3.03 billion
• CAGR (2026-2035): 7.60%

Anti-Tuberculosis Therapeutics Market Overview

Anti-tuberculosis therapeutics comprise a broad class of pharmaceutical agents used to treat tuberculosis (TB), a contagious bacterial infection primarily caused by Mycobacterium tuberculosis. The market is driven by the persistently high global TB burden, rising incidence of MDR-TB and XDR-TB strains, heightened investment in innovative drug regimens, and expanding government initiatives for TB elimination. The market is poised to grow at a CAGR of 7.60% during 2026-2035. The growth is underpinned by advancing therapeutic pipelines and targeted public health programs across the regions.

Anti-Tuberculosis Therapeutics Market Growth Drivers

Rising Tuberculosis Burden to Boost the Market Value

The increasing burden of tuberculosis is a primary driver supporting the expansion of the anti-tuberculosis therapeutics market. The persistent prevalence of new and drug-resistant cases continues to intensify the demand for effective treatment options. Zhi Chen et al. 2025, highlighted that 10.8 million new tuberculosis cases were reported globally in 2023, including a significant proportion of multidrug-resistant and HIV co-infected patients. The high mortality rate further emphasizes the urgent need for improved therapeutic interventions, thereby accelerating innovation and fueling long-term market growth.

Anti-Tuberculosis Therapeutics Market Trends

The market is witnessing key trends, including the advancement of shorter, universal treatment regimens.

Advancement of Shorter, Universal Treatment Regimens to Accelerate the Market Expansion

The growing focus on developing shorter, simplified, and universally effective tuberculosis treatment regimens is emerging as a significant trend in the market. Efforts are increasingly directed toward combination therapies that can address both drug-sensitive and drug-resistant forms. In August 2023, the PAN-TB collaboration, supported by the Bill & Melinda Gates Medical Research Institute, initiated a Phase 2b/c clinical trial evaluating novel multi-drug regimens designed to reduce treatment duration and eliminate the need for extensive drug-resistance testing. This innovation-driven approach is expected to enhance treatment outcomes and drive sustained market growth.

Anti-Tuberculosis Therapeutics Market Segmentation

Market Breakup by Disease Type

• Active Tuberculosis
• Latent Tuberculosis

Market Breakup by Therapy Type

• First Line Therapy
• Second Line Therapy

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Market Breakup by Dosage Form

• Tablets
• Capsules
• Injections
• Others

Market Breakup by End User

• Hospitals
• Specialty Clinics
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Market Breakup by Country

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Anti-Tuberculosis Therapeutics Market Share

Oral Route of Administration is Expected to Lead the Market

The market is segmented by route of administration into oral, parenteral, and others, reflecting diverse delivery preferences and clinical needs. Among these, the oral segment is expected to lead the market due to its ease of administration, improved patient compliance, and suitability for long-term treatment regimens. A key factor for the growth is the continued development of novel oral therapies with enhanced efficacy. For instance, in February 2023, Qurient Co. Ltd. and TB Alliance announced a licensing agreement for telacebec (Q203), a first-in-class orally available drug, highlighting ongoing innovation. This trend is expected to strengthen the dominance of oral therapies moving forward.

Anti-Tuberculosis Therapeutics Market Analysis by Region

The market is divided into regions such as the United States, the United Kingdom, Germany, France, Italy, Spain, Japan, and India. India is expected to account for the largest share of the market, driven by the country's persistently high tuberculosis disease burden and expanding government-driven TB elimination programs. According to the World Health Organization, India accounted for approximately 26% of all TB cases globally in 2023, positioning it as the highest disease-burden country among the eight major markets. The country's broad healthcare infrastructure, large patient population, robust national TB programs, and active adoption of novel drug regimens collectively reinforce its dominant market position.

Leading Players in the Anti-Tuberculosis Therapeutics Market

The key features of the market report comprise funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:

Johnson & Johnson Innovation Inc.

Johnson & Johnson Innovation Inc. is actively engaged in the market through awareness and treatment initiatives. The company supports campaigns such as MTV Nishedh in India to improve TB diagnosis and reduce stigma. It also advances access to its drug bedaquiline for multidrug-resistant TB, while collaborating with global partners to expand treatment reach and strengthen healthcare systems.

Pfizer Inc.

Pfizer Inc. is actively engaged in the market through its subsidiary Wyeth Pharmaceuticals LLC, which markets Trecator® (ethionamide tablets, USP). This oral therapy is indicated for treating active tuberculosis, particularly in drug-resistant cases. The product supports combination regimens to improve treatment outcomes and reflects the company’s continued role in addressing antimicrobial resistance and advancing tuberculosis care.

Sanofi SA

Sanofi SA is a global pharmaceutical company actively engaged in addressing tuberculosis through public health initiatives and access-to-medicine strategies. Through its TB FREE program in South Africa, the company supports treatment adherence using rifampicin-based therapies and DOTS protocols, strengthening its role in improving tuberculosis care delivery and expanding its presence in the anti-tuberculosis therapeutics landscape.

Eli Lilly and Company

Eli Lilly and Company is actively engaged in the anti-tuberculosis therapeutics market through sustained investment in early-stage drug discovery. The company recently expanded funding to the Infectious Disease Research Institute to advance novel therapies for tuberculosis and multidrug-resistant TB. It also contributes scientific expertise, compound libraries, and research tools, strengthening innovation and collaboration in developing more effective TB treatments.

Other key players in the market are AstraZeneca Plc, Viatris Inc. (Mylan N.V.), Teva Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries Ltd., Novartis AG, and Hikma Pharmaceuticals PLC.

Key Questions Answered in the Anti-Tuberculosis Therapeutics Market Report

• What was the anti-tuberculosis therapeutics market value in 2025?
• What is the anti-tuberculosis therapeutics market forecast outlook for 2026-2035?
• What major factors aid the demand for the anti-tuberculosis therapeutics market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major anti-tuberculosis therapeutics market trends?
• Which disease type is expected to dominate the market segment?
• Which therapy type is projected to lead the market segment?
• Which route of administration is anticipated to drive the market segment?
• Which dosage form segment is expected to record the fastest growth?
• Which end user segment is anticipated to hold the largest market share?
• Which distribution channel is likely to dominate the market segment?
• Who are the key players in the anti-tuberculosis therapeutics market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
• What country among the 8MM markets is expected to dominate the anti-tuberculosis therapeutics market?